Business context and reporting period
John Bean Technologies Corporation (JBT) filed this unaudited Form 10-Q for the quarter ended March 31, 2024. JBT provides technology, equipment and services to food and beverage businesses. The results are primarily for continuing operations; AeroTech was sold in August 2023, and its prior-period results are presented as discontinued operations.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $392.3 million | $388.5 million; up 1.0% |
| Gross profit / margin | $140.3 million / 35.8% | $132.9 million / 34.2%; margin up 160 bps |
| Operating income | $29.1 million | $28.4 million; up 2.5% |
| Continuing-operations income | $22.7 million; diluted EPS $0.71 | $17.1 million; diluted EPS $0.53 |
| Net income | $22.8 million; diluted EPS $0.71 | $27.2 million; diluted EPS $0.85 |
| Adjusted EBITDA from continuing operations | $57.4 million; 14.6% of revenue | $54.4 million; 14.0% of revenue |
| Continuing operating cash flow | $10.4 million | $11.4 million |
| Free cash flow (company-defined) | $0.7 million | $(4.5) million |
Revenue growth reflected higher pricing and increased non-recurring volume, partly offset by lower recurring volume. Recurring revenue was $202.8 million versus $219.3 million; non-recurring revenue was $189.5 million versus $169.2 million. Management attributed improved gross margin mainly to volume, pricing, restructuring and sourcing savings, partly offset by a mix shift toward lower-margin non-recurring revenue. SG&A increased $6.4 million to $110.1 million, primarily due to M&A costs and incentive compensation.
Net income declined mainly because Q1 2023 included $10.1 million of after-tax discontinued-operations income from AeroTech; continuing-operations income increased. Interest income rose to $5.7 million from $1.0 million, reflecting cash held after the AeroTech sale, while interest expense fell to $2.9 million from $7.5 million. The continuing-operations tax rate was 26.2%, versus 21.2%, including $1.0 million of unfavorable discrete items.
At March 31, 2024, cash and cash equivalents were $479.0 million, current assets $1,102.4 million and current liabilities $466.1 million. Long-term debt, net, was $647.0 million; gross borrowings were $652.5 million. The revolving facility had $250 million drawn and $1.0 billion available, subject to its leverage covenant. JBT reported compliance with all credit covenants. Total cash decreased $4.3 million during the quarter. Continuing operating, investing and financing activities used or provided $10.4 million, $(7.2) million and $(6.1) million, respectively.
Outlook, material developments and risks
- Management expects 2024 revenue growth, supported by organic initiatives and anticipated improvement in North American poultry investment, and expects margins to rise through sourcing initiatives, restructuring savings and continuous improvement. It expects positive cash flow for full-year 2024 and capital expenditures of $45–55 million.
- Demand was healthy in ready meals, convenience foods, and fruit and vegetables; management noted select North American softness, including timing of warehouse automation orders and continued slower poultry investment.
- The restructuring plan had generated $14.3 million of cumulative savings by March 31, 2024; management expects total cumulative savings of $18–20 million and another $4–5 million during the remainder of 2024. No additional restructuring actions were expected as of quarter-end.
- On April 4, 2024, after quarter-end, JBT signed a transaction agreement for a voluntary offer for Marel. Marel shareholders may elect cash, JBT shares or a combination, subject to proration; the planned transaction is subject to shareholder, regulatory and other conditions. JBT arranged €1.9 billion of secured bridge financing, conditional on closing, and reported approximately $20 million in related financing costs incurred. It expects $30–35 million of pre-close transaction costs to reduce 2024 operating cash flow and approximately $7.5 million of bridge-agreement cash impact from financing activities in 2024.
- Key transaction risks include failure or delay to obtain approvals or satisfy offer conditions, integration and synergy execution, shareholder dilution, and substantially higher combined-company debt and borrowing costs. Other disclosed business risks include economic and supply-chain disruption, inflation, foreign exchange, customer and contract risks, competition, cybersecurity and geopolitical events. Management said pending legal matters were not expected to have a material adverse effect overall, though an unfavorable resolution could materially affect an individual future period.
Important facts for investors to verify
- Progress toward Marel offer conditions, approvals, expected timing, financing needs and total transaction costs.
- Whether revenue growth and the expected North American poultry recovery materialize, and the balance between recurring and non-recurring sales.
- Delivery of planned margin expansion and restructuring savings, alongside rising SG&A and M&A expenses.
- Cash conversion and working-capital trends, including advance customer payments, receivables and inventory.
- Debt, covenant headroom and financing costs if the proposed Marel transaction closes.